Business

Hyderabad based BioGenex develops Direct RT-PCR Kit which detects all variants of Covid-19 Double Quick

Jan 13, 2022

Hyderabad (Telangana) [India], January 13 (ANI/BusinessWire India): BioGenex Life Sciences Pvt Ltd. has developed a RT-PCR kit for Covid-19 diagnosis, which detects COVID 19 caused by SARS COV 2 variants including "OMICRON" plus other variants.
The NIB, Noida, an ICMR designated lab, examined the performance of this kit and found that it performed with 100% accuracy which means no false negatives or positives, which will significantly control the pandemic through accurate diagnosis. The kit detects Omicron variant in half the time than standard RT-PCR test.
The TRIPLEX COVID-19 RT-PCR Direct is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 directly from the upper respiratory swab, nasopharyngeal or oropharyngeal swabs, collected in preservative media, (VTM/UTM), pH 7.2-7.4 to provide the molecular diagnostic basis for infected patients.
This test analyses samples in VTM directly without the need for RNA extraction step. It helps scientists for rapid tracking of disease prevalence and aid in treatment insight (e.g. hospital beds, oxygen ventilators and expensive medications) for healthcare systems in making appropriate measures to combat COVID-19.
There are many challenges associated with ramping up testing capacity, due to supply chain delays and shortage of extraction reagents, this situation call-up for alternative protocols to ensure the continuity of testing in laboratories. Due to increased demand for SARS-CoV-2 variants screenings, an alternative protocol with similar sensitivity is required, said Dr. Krishan Kalra, CEO BioGenex.
He further added, "Sustained surveillance is essential for public health. Our latest tests reduce the cost of testing and turnaround time for the result. As we learn from the pandemic, we are partnering with concerned organizations to understand and strengthen our diagnostic portfolio to develop-deliver reliable and sustainable diagnostic solutions in the future."
For more info on COVID 19 products please visit: www.ingenuityd.com. IngenuityD is a special spinoff from BioGenex which caters to COVID 19 diagnostic market.
This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

More news

KARAM Safety acquires Midas Safety India to strengthen its leadership position in the personal protection equipment (PPE) industry in India

New Delhi [India], May 3: KARAM Safety, a leading global PPE player and fall protection solutions provider, is pleased to announce the successful acquisition of Midas Safety India, a prominent player in the hand protection safety products industry. This strategic move marks a significant milestone in KARAM Group's journey towards expanding its presence and enhancing its product offerings. The acquisition of Midas Safety India strengthens KARAM Group's position as a market leader in the safety industry, combining KARAM's expertise in fall protection and personal protective equipment (PPE) with Midas Safety India's extensive portfolio of hand protection safety products. This synergy will enable KARAM Group to offer customers a comprehensive range of high-quality safety solutions to meet their evolving needs.

May 03, 2024